Company intelligence / Profile preview

Lytica Therapeutics

Cambridge, Massachusetts, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Lytica Therapeutics develops antibody-drug conjugates using a proprietary stapled antimicrobial peptide technology designed to improve cellular internalization. Their lead preclinical program targets folate receptor alpha in oncology. The company also explores applications in antimicrobials using their stapled peptide approach. No published clinical results are available yet.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugates (ADCs)Stapled antimicrobial peptides ("stamps")Peptide therapeutics
Industry: Biotech

Partnerships

Investors include CARB-X and JLabs; no major pharma partnerships disclosed.

Beyond the preview

Go deeper on Lytica Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lytica Therapeutics.

Explore the full profile